Pivotal Progresses with Vascazen - Analyst Blog

By
A A A

Pivotal Therapeutics Inc. ( PVTTF ) recently announced encouraging top line data from the REVEAL study (n=110) on its cardiovascular candidate Vascazen in the US. Vascazen was successful in achieving the primary objective of the study of correcting Omega-3 deficiency.

Results from the study also revealed that Vascazen gained statistical significance in several other secondary objectives in patients having elevated triglycerides. The REVEAL trial is a randomized, double blind, placebo controlled, multi-center study. Pivotal Therapeutics enrolled 110 patients for the study.

The study evaluated the effects of Vascazen in the correction of Omega-3 deficiency in patients suffering from cardiovascular disease and having one or more risk factors associated with it. Moreover, the concomitant effects of Vascazen on cardiovascular risk factors including triglycerides, very-low-density lipoprotein (VLDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol among others, were also evaluated.

Pivotal Therapeutics stated in its press release that the positive top line data from the REVEAL study on Vascazen has been accepted for presentation at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2013 Scientific Sessions (ATVB).

We note that the cardiovascular market currently includes big players like Roche Holding ( RHHBY ) and Sanofi ( SNY ).

We note that Vascazen is the lead product at Pivotal Therapeutics. Vascazen is formulated to meet the dietary Omega-3 deficient needs of patients suffering from cardiovascular diseases.

Pivotal Therapeutics currently carries a Zacks Rank #3 (Hold). Meanwhile other speciality pharmaceutical companies such as Biodel Inc. ( BIOD ) currently look better positioned. Biodel carries a Zacks Rank #2 (Buy).



BIODEL INC (BIOD): Free Stock Analysis Report

PIVOTAL THERAPT (PVTTF): Get Free Report

ROCHE HLDG LTD (RHHBY): Get Free Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BIOD , LDL , PVTTF , RHHBY , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Why Bankers Are Dishonest
Why Bankers Are Dishonest           

Stocks

Referenced

Most Active by Volume

61,589,609
  • $35.95 ▲ 4.66%
52,206,120
  • $39.92 ▼ 2.49%
48,647,533
  • $17 ▼ 0.35%
41,081,140
  • $9.71 ▲ 2.32%
38,883,256
  • $116.31 ▲ 1.43%
35,895,170
  • $109.82 ▲ 0.92%
28,527,465
  • $8.98 ▲ 2.39%
28,391,104
  • $8.69 ▲ 1.40%
As of 11/20/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com